SR-8541A
Phase 2Small molecule
SR-8541A is one of 32 small molecule programs targeting Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC). It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
50 competitors in Advanced/metastatic Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Fludara
SanofiPhase 2
Tagrisso
AstraZenecaPhase 2
Xtandi
AstellasPhase 2
Zytiga
Johnson & JohnsonPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Herceptin
OOrganon and Co
Phase 2
Sporanox
SSebela Pharmaceuticals Development LLC
Phase 2
Albumin-Bound Paclitaxel
Bristol-Myers SquibbPhase 2
BNT327
BioNTechPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SR-8541A. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SStingray Therapeutics